This descriptive-analytical study was conducted in 2014 - 2015 on women who had been diagnosed with BC in 2008 - 2014 and had received cancer treatments for at least 3 months before recruitment to the study. Initially, a list of all eligible women was created based on the data available from the cancer record center in South Khorasan, Iran. Then, a telephone contact was made with each eligible woman to inform her about the study and invite her to participate. Women who agreed to participate were asked to refer to the social determinants of health research center of Birjand University of Medical Sciences, Birjand, Iran. In the center, they were asked to complete the study questionnaires.
Data collection was done through holding face-to-face interviews with each woman for completing the following 3 questionnaires:
1. A researcher-made demographic and clinical characteristics questionnaire: This questionnaire included items on age, height, weight, breastfeeding history, educational status, marital status, employment status, number of children, husbands’ employment status, husband’s educational status, family income, family financial status, BC grade, treatment type, length of treatment, family history of BC, and history of affliction by other illnesses.
2. The 30-item EORTC core quality of life questionnaire (EORTC QLQ-C30): This questionnaire was developed by the European organization for research and treatment of cancer. Thirteen items of the questionnaire are grouped into a symptom scale on the complications of cancer and chemotherapy such as fatigue (3 items), pain (2 items), nausea and vomiting (2 items), dyspnea (1 item), appetite loss (1 item), insomnia (1 item), constipation (1 item), diarrhea (1 item), and financial difficulties (1 item). Items are scored on a four-point Likert-type scale from 1 to 4, resulting in a total symptom scale score of 13 - 52. The remaining 17 items are labeled on a functional scale and are related to physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items), and global health status (2 items). The first 15 items of the functional scale are scored from 1 to 4, while the 2 items on global health status are scored from 1 to 7. Therefore, the total score of the functional scale can range from 17 to 74.
3. The 23-item EORTC breast cancer quality of life questionnaire (EORTC QLQ BR23): this questionnaire also includes a functional and a symptom scale. The 8 items of the functional scale are related to body image (4 items), sexual functioning (2 items), sexual enjoyment (1 item), and future perspective (1 item). These 8 items are scored 1 - 4, resulting in a total score of 8 - 32. The remaining 15 items of this questionnaire form a symptom scale and are systematic therapy side effects (7 items), breast symptoms (4 items), arm symptoms (3 items), and upset by hair loss (1 item). These items are also scored 1 - 4 and the total score of symptom scale is 15 - 60.
In order to facilitate inter-scale comparison, the total score of each scale was changed to a 1 - 4 scale through dividing it by the number of items in that scale. Higher total QOL scores represent better QOL. On the other hand, higher functional scale scores indicate higher functional status, while higher scores for the symptom scale stand for lower status. The total 1 - 4 score of QOL is interpreted as follows: scores 1 - 2.49: low QOL; scores 2.5 - 3.24: moderate QOL; and scores 3.25 - 4: high QOL.
The Persian versions of both QLQ-C30 and QLQ-BR23 were reported to have great validity and reliability (
14,
15) with Cronbach’s alpha values of 0.63 - 0.95 (
16). The Cronbach’s alpha values of the questionnaires and their scales in this study were 0.77 - 0.88.
Collected data were entered into the SPSS software (v. 16.0). The two-way analysis of variance was employed for data analysis at a significance level of less than 0.05.